Biovitrum wins contract for Resistentia protein

Biovitrum’s assignment is to develop the existing process for the biotechnical manufacturing of RES 08 to a standard that meets the demands of a clinical phase III trial, and furthermore to manufacture sufficient amounts of the substance for the trial. The project will run for more than two years beginning in November 2006.

With the onset of an allergic reaction, allergy antibodies (IgE, immunoglobulin E, a specific protein in our immune system) are formed against a specific substance. Resistentia has developed the protein drug candidate RES 08 that blocks the effect of IgE preventing an allergic reaction.

“The agreement which involves both process development and manufacturing of the biopharmaceutical drug substance for this clinical phase III trial, means that we will utilize our extensive expertise and broad experience in protein pharmaceuticals to the full extent,” stated Hans Orstrom, senior vice president, Biovitrum Biopharmaceuticals.